AC Immune SA
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AC Immune SA
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
The company’s new blockbuster eye treatment helped it maintain growth in 2023, while 2024 will see more strategic updates as the company broadens its disease area focus.
Deal Snapshot: Roche is finally returning the rights to two failed Alzheimer’s candidates. But why now?
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- AC Immune, Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.